tradingkey.logo

BUZZ-Supernus rises after FDA approves its drug-device combination for Parkinson's disease

ReutersFeb 4, 2025 4:08 PM

Shares of Supernus Pharmaceuticals SUPN.O rise 6.2% to $39.67

SUPN says U.S. FDA has approved its drug-device combination, Onapgo, to treat movement-related symptoms of Parkinson's disease

Approval comes after previous declines in 2022 and 2024 due to quality and device concerns

SUPN says Onapgo will be available in United States in Q2 and is expected to generate $200 mln to 300 mln in peak sales

SUPN gained 30.4% in 2024

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI